02 — Hallmarks of Cancer

Core Explanation

In 2000, Douglas Hanahan and Robert Weinberg proposed that the vast diversity of cancer genotypes converges on a limited set of functional capabilities — the Hallmarks of Cancer — that cells must acquire to become malignant. This framework, updated in 2011, organizes cancer biology around the capabilities a cell must gain (and the safeguards it must lose) to form a clinically significant tumor. The hallmarks are not a checklist of mutations; they are acquired functional properties that can be achieved through diverse molecular mechanisms.

The Original Six Hallmarks (2000)

1. Sustaining Proliferative Signaling

Normal cells require extracellular growth factors to divide. Cancer cells short-circuit this requirement through multiple strategies:

• Autocrine signaling: The cell produces its own growth factors (e.g., TGF-α production by glioblastomas).
• Receptor overexpression: Amplification of receptor tyrosine kinases (e.g., HER2/ERBB2 amplification) makes cells hypersensitive to ambient ligand levels.
• Ligand-independent receptor activation: Truncated receptors (e.g., EGFRvIII in glioblastoma) or mutations that lock kinases in active conformations.
• Constitutive downstream pathway activation: Oncogenic Ras mutations bypass the need for RTK signaling entirely; B-Raf(V600E) constitutively activates MAPK signaling.
• Disruption of negative feedback: Loss of PTEN (a phosphatase that degrades PIP₃) leaves PI3K/Akt signaling perpetually on.

2. Evading Growth Suppressors

Tumor suppressors normally enforce cell-cycle arrest, differentiation, or senescence. Cancer cells disable these brakes. The two canonical examples are:

• Rb pathway: Inactivation through RB1 mutation, CDK4 amplification, or CDKN2A (p16) deletion removes the G₁→S checkpoint.
• p53 pathway: TP53 mutation disables DNA-damage-induced arrest, senescence, and apoptosis.
• TGF-β resistance: Many late-stage tumors lose responsiveness to TGF-β's cytostatic effects while retaining (or co-opting) its effects on epithelial–mesenchymal transition (EMT) and immune suppression.

3. Resisting Cell Death

Cancer cells evade apoptosis through:

• Loss of p53 (no PUMA/NOXA transcription).
• Bcl-2 overexpression, commonly through chromosomal translocation (e.g., t(14;18) in follicular lymphoma placing BCL2 under the IgH enhancer) or gene amplification.
• Downregulation of death receptors (Fas/CD95).
• Upregulation of decoy receptors that bind ligands without transmitting death signals.
• Overexpression of IAPs (XIAP, survivin).

4. Enabling Replicative Immortality

Normal somatic cells have a finite replicative lifespan governed by telomere shortening. Cancer cells must overcome this barrier (see Topic 8-03 for mechanism). Most (85–90%) do so by upregulating telomerase (hTERT expression); a minority use the ALT (alternative lengthening of telomeres) pathway based on homologous recombination.

5. Inducing Angiogenesis

Tumors cannot grow beyond ~1–2 mm³ without a blood supply — diffusion of oxygen and nutrients becomes limiting. The angiogenic switch involves:

• Upregulation of pro-angiogenic factors: VEGF-A (vascular endothelial growth factor), FGF, PDGF.
• Downregulation of angiogenic inhibitors: thrombospondin-1, endostatin, angiostatin.
• VEGF expression is driven by hypoxia via HIF-1α (hypoxia-inducible factor 1α), which is stabilized when oxygen is low and transcribes VEGFA and other hypoxia-response genes.

The resulting tumor vasculature is structurally abnormal — tortuous, leaky, and chaotically organized — which impairs drug delivery and creates regions of severe hypoxia that select for more aggressive clones.

6. Activating Invasion and Metastasis

The hallmark with the greatest clinical impact: ~90% of cancer deaths are due to metastases. The multi-step invasion-metastasis cascade (local invasion, intravasation, circulation survival, extravasation, colonization) is detailed in Topic 8-03. Key molecular changes include:

• Loss of E-cadherin (a cell–cell adhesion molecule), often through transcriptional repression by EMT transcription factors (Snail, Slug, Twist, ZEB1/2).
• Upregulation of matrix metalloproteinases (MMPs) that degrade extracellular matrix.
• Switch in integrin expression to favor migration over adhesion.

The Next Generation: Four New Hallmarks (2011)

7. Deregulating Cellular Energetics (Metabolic Reprogramming)

Even in the presence of oxygen, many cancer cells preferentially convert glucose to lactate rather than oxidizing it completely in mitochondria — the Warburg effect or aerobic glycolysis. This is not a metabolic defect; it is a deliberate reprogramming that supports biosynthesis:

• Glycolytic intermediates are diverted into the pentose phosphate pathway (ribose-5-phosphate for nucleotides) and serine/glycine synthesis (amino acids, one-carbon metabolism).
• Lactate secretion acidifies the tumor microenvironment, promoting invasion and immune suppression.
• Glutamine becomes a major carbon and nitrogen source, feeding the TCA cycle and biosynthesis.
• Oncogenes (Myc, Ras, Akt) and tumor suppressors (p53, PTEN) directly regulate metabolic enzymes, making metabolic reprogramming a direct consequence of oncogenic mutations rather than an epiphenomenon.

8. Avoiding Immune Destruction

The immune system can recognize and eliminate nascent tumor cells through immunosurveillance (a concept originally proposed by Burnet and Macfarlane Burnet, then validated experimentally). To become clinically apparent, tumors must evade this surveillance. Mechanisms include:

• Immune checkpoint exploitation: Tumor cells upregulate PD-L1, which binds PD-1 on tumor-infiltrating cytotoxic T cells, delivering an inhibitory signal that exhausts or anergizes them. This is the target of checkpoint inhibitor immunotherapies (anti-PD-1: pembrolizumab/nivolumab; anti-PD-L1: atezolizumab; anti-CTLA-4: ipilimumab).
• Secretion of immunosuppressive cytokines (TGF-β, IL-10).
• Recruitment of immunosuppressive cells: Regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs) polarized to an M2 phenotype.
• Downregulation of MHC class I, impairing antigen presentation.
• Selection of non-immunogenic clones (immunoediting) — the immune system sculpts the tumor, eliminating clones that express strong neoantigens and leaving behind those that are immunologically invisible.

9. Tumor-Promoting Inflammation

Chronic inflammation is a risk factor for many cancers (e.g., H. pylori → gastric cancer, inflammatory bowel disease → colorectal cancer, hepatitis → hepatocellular carcinoma). In established tumors, inflammatory cells in the microenvironment actively promote progression by:

• Supplying growth factors (EGF, HGF) and pro-angiogenic factors (VEGF).
• Producing ROS that accelerate mutation.
• Secreting MMPs that facilitate invasion.
• Suppressing adaptive immunity.

10. Genome Instability and Mutation

Genome instability is both a hallmark and an enabling characteristic — it is the engine that generates the genetic diversity upon which clonal selection acts. Two broad classes:

• Chromosomal instability (CIN) — gains/losses of whole chromosomes or large segments; driven by mitotic errors, cohesion defects, centrosome amplification, or telomere dysfunction.
• Microsatellite instability (MSI) — defects in DNA mismatch repair (MLH1, MSH2, MSH6, PMS2) cause mutations in short repeated sequences.

Enabling Characteristics (2011)

Two properties facilitate hallmark acquisition:

Genome Instability and Mutation

(Overlaps with hallmark #10 — elevated to an enabling characteristic because it accelerates acquisition of all other hallmarks.)

Tumor-Promoting Inflammation

(Overlaps with hallmark #9 — also an enabling characteristic because inflammatory environments promote genomic damage and select for malignant clones.)

Questions

Q1: How does the Warburg effect benefit a tumor cell beyond simply producing ATP?

A1: Aerobic glycolysis produces only 2 ATP per glucose vs. ~36 from oxidative phosphorylation, so ATP production is not the rationale. The benefits are biosynthetic: (1) Glycolytic intermediates (glucose-6-phosphate, 3-phosphoglycerate) are diverted into the pentose phosphate pathway (ribose for nucleotides) and serine biosynthesis (amino acids, one-carbon units for methylation and nucleotide synthesis). (2) The increased flux through glycolysis generates abundant NADPH via the pentose phosphate pathway, which fuels fatty acid synthesis and maintains redox balance. (3) Lactate secretion acidifies the microenvironment, inhibiting immune cells and promoting matrix degradation. (4) Rapid glucose consumption outcompetes infiltrating T cells for glucose, contributing to immune evasion. (5) Oncogenic mutations (Myc, Ras, PI3K) directly upregulate glucose transporters and glycolytic enzymes, making the Warburg effect a direct downstream consequence of the same mutations that drive proliferation — the cell is programmed to use glucose for building blocks, not just burning it for energy.

Q2: Immunotherapy with anti-PD-1 antibodies produces durable remissions in a subset of patients. What tumor properties predict response, and why doesn't it work in all patients?

A2: Response predictors include: (1) High tumor mutational burden (TMB) — more mutations → more neoantigens → more T-cell recognition; (2) PD-L1 expression on tumor cells; (3) Pre-existing CD8+ T-cell infiltration at the tumor margin (a "hot" or "inflamed" tumor); (4) Microsatellite instability (MSI-high) or mismatch repair deficiency. Resistance mechanisms include: low mutational burden ("cold" tumors with no neoantigens), loss of MHC class I expression (no antigen presentation), defects in interferon-γ signaling (JAK1/JAK2 mutations), β-catenin pathway activation (excludes T cells from the tumor microenvironment), upregulation of alternative immune checkpoints (TIM-3, LAG-3), and recruitment of MDSCs/Tregs. The fundamental requirement is that the immune system must already recognize the tumor; checkpoint blockade only removes the brakes — it doesn't start the engine if no T cells recognize tumor antigens.

Q3: Why is genome instability classified as both a hallmark and an enabling characteristic?

A3: Genome instability generates the mutation rate necessary for a single cell to acquire all six (or more) hallmarks within a human lifespan. Spontaneous mutation rates (~10⁻⁹ per base per division) are too low; a cell must first acquire a "mutator phenotype" — a defect in a stability gene (DNA repair, checkpoint, mitotic machinery) — that elevates its mutation rate 10–1000-fold. This genome instability is itself selected for because it accelerates evolution, but it is not a "goal" of the cancer cell in the way proliferation is. Hence it is both a trait the cell acquires (hallmark) and a property that enables the acquisition of all other traits (enabling characteristic). It explains why cancers progress: the tumor becomes progressively more genomically unstable, which generates progressively more aggressive subclones. It also explains therapy resistance — a genomically unstable population has pre-existing resistant variants before treatment even starts.